Skip to search formSkip to main contentSkip to account menu

siltuximab

Known as: Anti-IL-6 Chimeric Monoclonal Antibody 
A chimeric, human-murine, monoclonal antibody targeting the pro-inflammatory cytokine interleukin 6 (IL-6), with antitumor and anti-inflammatory… 
National Institutes of Health

Related topics

Related topics

7 relations

Broader (2)

Antineoplastic AgentsMonoclonal Antibodies
NCIt Antineoplastic Agent Terminologyantigen bindingsiltuximab 100 MG Injection [Sylvant]

Narrower (2)

cClB8 monoclonal antibodymonoclonal antibody CNTO 328

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
Review
2020
Clinical outcomes in COVID‐19 patients treated with tocilizumab: An individual patient data systematic review
Current evidence suggests an important role of the interleukin‐6 (IL‐6) pathway in severe acute respiratory syndrome coronavirus… 
2019
2019
Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab in High-Risk Smoldering Multiple Myeloma
Purpose: IL6 is important for the growth and survival of myeloma cells. This study evaluated blocking IL6 with siltuximab to… 
Highly Cited
2015
Highly Cited
2015
Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman…
Purpose: Siltuximab (IL6 antibody) is approved for the treatment of multicentric Castleman disease (MCD). Effects of IL6… 
Highly Cited
2010
Highly Cited
2010
Castleman disease in the 21st century: an update on diagnosis, assessment, and therapy.
Castleman disease (CD) is a nonclonal lymphoproliferative disorder that can affect single lymph node stations or, alternatively… 
Highly Cited
2010
Highly Cited
2010
Preliminary evidence of an association between a functional interleukin-6 polymorphism and fatigue and sleep disturbance in oncology patients and their family caregivers.
Highly Cited
2010
Highly Cited
2010
Effects of Siltuximab on the IL-6–Induced Signaling Pathway in Ovarian Cancer
Purpose: To explore potential therapeutic strategies for interrupting the interleukin-6 (IL-6) signaling pathway, we measured IL… 
Highly Cited
2009
Highly Cited
2009
A High-Affinity Fully Human Anti–IL-6 mAb, 1339, for the Treatment of Multiple Myeloma
Purpose: We investigated the in vitro and in vivo anti-multiple myeloma activity of monoclonal antibody (mAb) 1339, a high… 
Highly Cited
2005
Highly Cited
2005
Diurnal variation of lipopolysaccharide-induced alterations in sleep and body temperature of interleukin-6-deficient mice
Highly Cited
1997
Highly Cited
1997
Sickness behavior in mice deficient in interleukin-6 during turpentine abscess and influenza pneumonitis.
Interleukin-6 (IL-6), among other cytokines, is thought to be involved in the regulation of sickness behavior (e.g., anorexia… 
Highly Cited
1993
Highly Cited
1993
Antibodies chaperone circulating IL-6. Paradoxical effects of anti-IL-6 "neutralizing" antibodies in vivo.
In the baboon or the mouse, a stimulus such as LPS, TNF, or IL-1 typically led to a rapid induction of circulating IL-6, the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)